Ken Griffin Madrigal Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 57,000 shares of MDGL stock, worth $13.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,000

Previous 110,700 48.51%

Holding current value

$13.3 Million

Previous $29.6 Million 45.98%

% of portfolio

0.0%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $2.59 Million - $3.92 Million	-13,422 Reduced 54.53%	11,190 $3.13 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $2.42 Million - $4 Million	14,120 Added 134.58%	24,612 $6.57 Million
Q4 2023 Feb 14, 2024	SELL	$120.4 - $237.13 $32.1 Million - $63.2 Million	-266,334 Reduced 96.21%	10,492 $2.43 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $28.2 Million - $43.6 Million	192,917 Added 229.91%	276,826 $40.4 Million
Q2 2023 Aug 14, 2023	SELL	$203.88 - $312.0 $10.2 Million - $15.7 Million	-50,235 Reduced 37.45%	83,909 $19.4 Million
Q1 2023 May 15, 2023	SELL	$231.06 - $307.08 $8.35 Million - $11.1 Million	-36,143 Reduced 21.22%	134,144 $32.5 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $7.48 Million - $38 Million	128,143 Added 304.06%	170,287 $49.4 Million
Q3 2022 Nov 14, 2022	SELL	$60.57 - $79.51 $632,532 - $830,322	-10,443 Reduced 19.86%	42,144 $2.74 Million
Q2 2022 Aug 15, 2022	SELL	$58.04 - $100.2 $398,444 - $687,873	-6,865 Reduced 11.55%	52,587 $3.77 Million
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $114,518 - $208,772	-2,049 Reduced 3.33%	59,452 $5.83 Million
Q4 2021 Feb 14, 2022	BUY	$72.34 - $95.09 $2.12 Million - $2.79 Million	29,313 Added 91.07%	61,501 $5.21 Million
Q3 2021 Nov 15, 2021	SELL	$78.35 - $105.02 $10.1 Million - $13.5 Million	-128,807 Reduced 80.01%	32,188 $2.57 Million
Q2 2021 Aug 16, 2021	SELL	$97.2 - $137.59 $5.72 Million - $8.09 Million	-58,810 Reduced 26.76%	160,995 $15.7 Million
Q1 2021 May 17, 2021	BUY	$108.54 - $125.2 $23.1 Million - $26.6 Million	212,612 Added 2955.82%	219,805 $25.7 Million
Q4 2020 Feb 16, 2021	SELL	$110.06 - $133.7 $13 Million - $15.8 Million	-118,491 Reduced 94.28%	7,193 $799,000
Q3 2020 Nov 16, 2020	BUY	$99.78 - $124.21 $7.38 Million - $9.19 Million	74,010 Added 143.22%	125,684 $14.9 Million
Q2 2020 Aug 14, 2020	SELL	$60.13 - $125.71 $1.19 Million - $2.49 Million	-19,771 Reduced 27.67%	51,674 $5.85 Million
Q1 2020 May 15, 2020	BUY	$66.76 - $93.49 $1.99 Million - $2.79 Million	29,836 Added 71.71%	71,445 $4.77 Million
Q4 2019 Feb 14, 2020	SELL	$84.28 - $118.5 $1.56 Million - $2.19 Million	-18,507 Reduced 30.79%	41,609 $3.79 Million
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $3.93 Million - $4.95 Million	-46,509 Reduced 43.62%	60,116 $5.18 Million
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $8.52 Million - $13.3 Million	93,462 Added 710.04%	106,625 $11.2 Million
Q1 2019 May 15, 2019	BUY	$103.48 - $143.84 $337,241 - $468,774	3,259 Added 32.91%	13,163 $0
Q4 2018 Feb 14, 2019	SELL	$94.77 - $215.54 $218,918 - $497,897	-2,310 Reduced 18.91%	9,904 $1.12 Million
Q3 2018 Nov 13, 2018	BUY	$207.3 - $300.31 $150,914 - $218,625	728 Added 6.34%	12,214 $0
Q2 2018 Aug 10, 2018	SELL	$101.55 - $313.9 $18.2 Million - $56.2 Million	-179,167 Reduced 93.98%	11,486 $0
Q1 2018 May 11, 2018	SELL	$93.35 - $149.04 $17.8 Million - $28.4 Million	-190,674 Reduced 50.0%	190,653 $22.3 Million
Q4 2017 Feb 09, 2018	BUY	$39.35 - $97.37 $15 Million - $37.1 Million	381,327	381,327 $35 Million

Others Institutions Holding MDGL

# of Institutions

297

Shares Held

22M

Call Options Held

757K

Put Options Held

370K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $3.99B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account